Journal article
Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): Study design and baseline characteristics
Abstract
BACKGROUND: Rosiglitazone, a thiazolidinedione, has effects on insulin sensitivity and cardiovascular risk factors that may favorably impact the progression of coronary atherosclerosis.
METHODS: APPROACH is a double-blind randomized clinical trial comparing the effects of the insulin sensitizer rosiglitazone with the insulin secretagogue glipizide on the progression of coronary atherosclerosis. Patients with type 2 diabetes and coronary artery …
Authors
Ratner RE; Cannon CP; Gerstein HC; Nesto RW; Serruys PW; van Es G-A; Kolatkar NS; Kravitz BG; Zalewski A; Fitzgerald PJ
Journal
American Heart Journal, Vol. 156, No. 6, pp. 1074–1079
Publisher
Elsevier
Publication Date
December 2008
DOI
10.1016/j.ahj.2008.07.025
ISSN
0002-8703